- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02835989
Community Paramedicine at Home (CP@Home)
Community Paramedicine at Home (CP @Home)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S4K1
- McMaster University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 3 or more EMS calls in the last 6 months from intervention start date AND active caller in the last 30 days OR
- Any call for a lift assist to EMS in the past 30 days OR
- Paramedic referral into program (identified by paramedic through usual practice)
Exclusion Criteria:
- Individuals living in long term care facilities
- Individuals currently involved in a home visit or social navigator program
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Styring
Sædvanlig pleje
|
|
|
Eksperimentel: CP@Home Intervention
The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician. The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity. |
Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call.
Participants will complete the informed consent process with a CP on their first visit.
This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home.
As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms.
A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period.
A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation.
It is anticipated the patient will be discharged from the CP@Home program at this point.
If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in number of repeat EMS calls
Tidsramme: Baseline and 1 year
|
Individual-level change in EMS call rate resulting in ambulance dispatch (pre-post intervention)
|
Baseline and 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in number of ED presentations
Tidsramme: Baseline and 1 year
|
Individual-level change in number of ED presentations (pre-post)
|
Baseline and 1 year
|
|
Change in number of hospital admissions
Tidsramme: Baseline and 1 year
|
Individual-level change in number of hospital admissions (pre-post)
|
Baseline and 1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Gina Agarwal, MBBS MRCGP CCFP PhD, McMaster University
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2153
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kardiovaskulær sygdom
-
Ottawa Hospital Research InstituteAfsluttetStress | Crisis Resource Management (CRM) færdigheder | Advanced Cardiovascular Life Support (ACLS) færdighederCanada
Kliniske forsøg med CP@Home
-
National University, SingaporeNational University Hospital, SingaporeAfsluttet
-
Burapha UniversityAfsluttetRis serum | Ris maske | RisgeleThailand
-
PfizerAfsluttetFedmeForenede Stater, Australien, Canada, Brasilien, Slovakiet, Tjekkiet, Argentina, Tyskland, Mexico, Det Forenede Kongerige, Sverige
-
University of California, San FranciscoCalifornia Breast Cancer Research ProgramAfsluttet
-
Siemens Molecular ImagingAfsluttet
-
Kasr El Aini HospitalUkendtUrologiske kirurgiske procedurerEgypten
-
PfizerAfsluttetFedmeAustralien, Forenede Stater, Korea, Republikken, Spanien, Frankrig, Det Forenede Kongerige, Tyskland, Sverige, Argentina, Chile, Mexico
-
Tasca TherapeuticsRekrutteringIkke-småcellet lungekræft | Blærekræft | Kolorektalt karcinom | Maligniteter i faste tumorer | Bugspytkirtelkræft, avanceret eller metastatisk | Hoved og hals (HNSCC) | Småcellet lungekræft (SCLC)Forenede Stater
-
Abramson Cancer Center of the University of PennsylvaniaAfsluttetAvancerede solide tumorerForenede Stater
-
Abramson Cancer Center of the University of PennsylvaniaAfsluttet